Summary
Agilent Technologies has agreed to acquire ACEA Biosciences for an undisclosed amount.
ACEA makes a range of real-time cell analysis and cytometer products, software, and consummables for life science research purposes.
Agilent continues to acquire technologies that are differentiated and provide it with greater penetration of life science research and clinical analysis markets.
Looking for a community to discuss ideas with? IPO Edge features a chat room of like-minded investors sharing investing ideas and strategies. Start your free trial today »
Quick Take
Life science research and diagnostics equipment firm Agilent Technologies (A) has announced an agreement to acquire ACEA Biosciences for an undisclosed sum.
ACEA has developed real-time cell analyzer and flow cytometer products for life science research markets.
With the deal for ACEA, Agilent continues to execute on its initiatives to accelerate its penetration into biopharma research markets with differentiated technologies.
